What factors drove the changes in Mirum's revenue and profit?

What were the key takeaways from Mirum's earnings call?

What were the key takeaways from Mirum’s earnings call?

What is Mirum's gross profit margin?

What is the market's earnings forecast for Mirum next quarter?

What guidance did Mirum's management provide for the next earnings period?

What is Mirum's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Mirum year over year?

- **Revenue Growth:** 55% YoY to $521M in 2025; 2026 guidance $630-650M driven by LIVMARLI and pipeline expansion.
- **Pipeline Milestones:** 4 registrational readouts in 18 months (Volixibat PSC Q2 2026, Brelovitug HDV H2 2026).
- **Financial Strength:** $391M cash, positive 2025 operating cash flow, 2027 return to positive cash flow.
- **Strategic Investments:** $150M+ for Brelovitug CMC; 2026 R&D spend up 75% to $336M.

**【CEO Summary Section】**
- 2025 net product sales: $521 million (55% YoY growth), driven by LIVMARLI ($244M U.S., $115M intl.) and bile acid medicines ($161M). 2026 guidance: $630-650M.
- Pipeline expansion: Brelovitug (Hepatitis D) acquisition; 4 near-term registrational readouts (2026-2027).
- Key programs: Volixibat PSC (Q2 2026 data), Brelovitug HDV (H2 2026 interim), MRM 3379 Fragile X (2027 data).
- Financial strength: $391M cash, positive 2025 operating cash flow, 2027 return to positive cash flow.

**【CMO Pipeline Update】**
- **Volixibat (PSC):** VISTAS study on track for Q2 2026 top-line data; 20mg BID dose selected post interim analysis. Pruritus, bile acid reduction, and QoL metrics assessed.
- **Brelovitug (HDV):** Azure 1/3 Phase III trials enrolling well; 24-week interim data expected Q2 2026. Single-agent regimen targeting 65-82% viral response.
- **MRM 3379 (Fragile X):** Phase II Bloom study on track for 2027 data; FDA Fast Track designation.

**【CFO Financial Commentary】**
- Q4 2025 net product sales: $149M (50% YoY growth); full year $521M (55% YoY).
- Operating expenses: $543M (2025); R&D $186M, SG&A $257M. Commercial cash margin: 55%.
- Cash position: $391M (up from $293M); $268.5M raised via private placements for Blue Jay acquisition.
- 2026 outlook: R&D spend increase (~$150M) for Brelovitug CMC; return to positive cash flow in 2027.

**【Q&A Highlights】**
- **Volixibat Pricing:** PBC pricing benchmark but final decision post-PSC data; no approved therapies in PSC.
- **PSC Study Design:** Enrollment requires persistent pruritus; safety database sufficient for NDA submission.
- **HDV Market:** ~200k global patients; Brelovitug single-agent regimen shows 100% viral response at 48w.
- **LIVMARLI Growth:** 2025 U.S. sales $244M; EXPAND study (cholestatic pruritus) on track for Q4 2026 data.
- **R&D Investment:** $150M increase for Brelovitug; 2026 R&D spend ~$336M (vs. 2025: $186M).

Mirum Pharmaceuticals, Inc.(MIRM)-20260226-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 revenue of $133 million (+47% YoY), driven by LIVMARLI U.S. expansion and international growth.
- **Pipeline Momentum**: VISTAS PSC Phase IIb study fully enrolled; interim data supports volixibat efficacy in PSC.
- **Financial Health**: GAAP net income of $3 million, cash balance of $378 million, and updated 2025 guidance of $500-510 million.
- **Strategic Focus**: Rare disease leadership with three $1B+ pipeline candidates (LIVMARLI, volixibat, MRM-3379).

**【CEO Opening Remarks】**
- Q3 2025 revenue: $133 million (47% YoY growth), driven by LIVMARLI U.S. and international expansion.
- Key milestones: VISTAS PSC Phase IIb study fully enrolled, GAAP net income of $3 million, and cash balance of $378 million.
- Strategic focus: Rare disease pipeline expansion, commercial execution, and financial discipline.

**【COO/Peter Radovich: Commercial Performance】**
- LIVMARLI net sales: $92 million (U.S.: $64M, international: $28M).
- Bile acid portfolio: $41 million, supported by CTEXLI FDA approval.
- Tablet formulation adoption: >50% of eligible patients switching from liquid.
- 2025 guidance updated to $500-510 million, reflecting Q4 international variability.

**【CMO/Joanne Quan: Pipeline Updates】**
- **VISTAS (PSC):** Enrollment complete; interim analysis supports efficacy; AASLD case series shows pruritus resolution in 50% of patients.
- **VANTAGE (PBC):** Interim data shows ITCH reduction and fatigue improvement; targeting 2026 readout.
- **EXPAND (cholestatic pruritus):** Enrolling well; BID dosing based on compassionate use success.
- **MRM-3379 (Fragile X):** Phase II initiated; preclinical data shows behavioral improvements.

**【CFO/Eric Bjerkholt: Financial Highlights】**
- Q3 GAAP net income: $3 million (vs. $10.2 million loss YoY).
- Operating expenses: $130 million (R&D: $43M, SG&A: $62M).
- Cash flow: $378 million (up $85 million YoY), enabling growth investments.

**【Q&A Highlights】**
- **LIVMARLI tablet adoption:** 50%+ of eligible patients switching, improving adherence.
- **Volixibat pricing:** Expected in $130-150k annual range, aligned with PBC peers.
- **IP portfolio strength:** Method patents for dosing in rare cholestatic diseases validated.
- **PSC safety:** No GI side effect concerns; DMC未提出修改方案.
- **BD strategy:** High bar for acquisitions, focused on underappreciated rare disease assets.

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript

- **Revenue surge**: Q2 2025 revenue $128M (+64% YoY), full-year guidance raised to $490-510M.
- **Pipeline momentum**: 3 pivotal trials (PSC, PBC, cholestatic pruritus) expected to report by Q2 2026.
- **Livmarli expansion**: Targeting $1+ billion with Alagille, PFIC, and ultra-rare cholestasis growth.
- **Cash strength**: $322M cash balance, operating cash flow positive for the quarter.
- **Fragile X progress**: Phase II trial to start Q4 2025 with 52 male patients.

**【CEO Summary Section】**
- Total Q2 2025 revenue reached $128 million, up 64% YoY, driven by Livmarli's strong performance across U.S. and international markets.
- Full-year 2025 revenue guidance raised to $490-$510 million (prev. $450-$470M), reflecting 49-51% YoY growth.
- Pipeline momentum: 3 pivotal trials expected to report by Q2 2026, including VISTAS (PSC), VANTAGE (PBC), and EXPAND (cholestatic pruritus).
- Long-term vision: Livmarli targeting $1+ billion annual revenue, with expansion into PFIC, Alagille, and ultra-rare cholestasis.

**【Commercial Performance (Peter Radovich)】**
- U.S. Livmarli sales: $57M (Q2), 70-75% 1-year persistence in Alagille, expanding into PFIC with later-onset diagnoses.
- International growth: $31M, including Takeda's Japan launch (June 2025) and partner market orders.
- Bile acid portfolio: $40M, benefiting from CTEXLI approval and steady demand.
- Tablet formulation launched in June, receiving positive patient feedback but no Q2 impact.

**【Pipeline Updates (Joanne Quan)】**
- VISTAS (PSC pruritus): Final patient screening in Q3, top-line data Q2 2026; confident in statistical power (SD 2 vs. 3).
- MRM-3379 (Fragile X): Phase II study to start Q4 2025, targeting 52 male patients (16-45) with full mutation.
- EXPAND (cholestatic pruritus): Enrollment on track for 2026, targeting ultra-rare cholestasis patients.

**【Financial Highlights (Eric Bjerkholt)】**
- Q2 2025: $128M revenue, $133M operating expenses (including $46M R&D, $63M SG&A).
- Cash flow positive for the quarter; cash balance $322M (up $29M YoY).
- Commercial cash contribution margin >50%, reflecting strong gross margin and expense control.

**【Q&A Key Highlights】**
- **Livmarli persistence**: ~70-75% 1-year retention in Alagille, PFIC too early to assess.
- **VISTAS confidence**: Statistical power assumptions conservative, baseline PSC population aligns with expectations.
- **Tablet impact**: Positive feedback, but Q2 sales unaffected; expect future contribution.
- **Fragile X trial**: FDA-cleared IND, Phase II to start Q4 2025 with 52 male patients.
- **Market penetration**: U.S. Alagille ~50% penetrated, PFIC expanding faster than expected.
- **EXPAND study**: Targeting ~1,000 patients with cholestatic pruritus from biliary atresia, Alagille variants, etc.
- **CTX growth**: Steady build post-approval, focusing on patient identification across specialties.
- **European strategy**: PFIC indication under review, direct market expansion in key geographies.

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: $111.6M revenue (+61% YoY), with full-year guidance raised to $435-$450M.
- **Three Key Approvals**: CTEXLI (U.S.), LIVMARLI (Japan, tablet), and Volixibat interim data showing durable pruritus reduction in PBC.
- **Pipeline Momentum**: VISTAS enrollment nears completion, Phase 2 Fragile X study to start in 2025, and LIVMARLI tablet adoption expected to drive switch demand.
- **Financial Strength**: Cash positive for Q1, 53% cash margin, and 10+ percentage point improvement in expense efficiency.

**【CEO Summary Section】**
- Q1 2025 total revenue reached $111.6 million, a 61% YoY increase, driven by strong growth across all three commercial medicines (LIVMARLI, CTEXLI, and bile acid products). Full-year guidance updated to $435-$450 million.
- Received three key regulatory approvals: CTEXLI for CTX in the U.S., LIVMARLI in Japan for PFIC/Alagille, and a single-tablet LIVMARLI formulation in the U.S.
- Pipeline progress: VISTAS study for Volixibat in PSC nearing enrollment completion (Q3 2025), interim data from VANTAGE study in PBC shows durable pruritus reduction (3.8-point baseline reduction, 2.5-point placebo-adjusted), and Phase 2 study for MRM-3379 in Fragile X expected to start in 2025.

**【CFO Financial Commentary】**
- Q1 2025 net product revenue: $111.6 million (vs. $69.2 million YoY). Cash position: $298.6 million (up from $292.8 million at Q1 2024).
- Operating expenses: $126.8 million (R&D: $46 million, SG&A: $57.7 million, COGS: $23 million). Includes $7 million one-time milestone payments.
- Cash flow positive for Q1 and expected for full year. Cash contribution margin improved to 53% (vs. 47% YoY). R&D and SG&A expenses as % of revenue decreased by over 10 percentage points YoY.

**【Commercial Highlights】**
- LIVMARLI: U.S. sales $49.5 million (70% YoY growth), international sales $23.7 million (includes $6 million in distributor inventory). Tablet formulation launched in Q2 2025 for patients >25 kg.
- CTEXLI: New CTX patient demand increasing post-FDA approval in Feb 2025. Focus on disease awareness in neurology, ophthalmology, and GI.
- Bile acid products: $38.4 million (47% YoY growth).

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript

- **Revenue Growth:** 2024 net product sales up 89% to $336.4M; 2025 guidance of $420-435M reflects 25%+ expansion.
- **Pipeline Momentum:** Volixibat (PSC/PBC pruritus) and MRM-3379 (Fragile X) advancing with 2026-2027 readouts; LIVMARLI EXPAND trial targets 1,000+ rare cholestatic patients.
- **Financial Strength:** $293M cash balance, positive 2025 cash flow guidance, and selective BD opportunities.
- **Strategic Focus:** Rare disease leadership through commercial execution (40% Alagille penetration), pipeline innovation, and disciplined capital allocation.

**【CEO Opening Remarks】**
- 2024 total net product sales: $336.4M (vs. $178.9M in 2023), driven by LIVMARLI ($213.3M, +50%) and bile acids ($123.1M). 
- 2025 guidance: $420-435M net product sales, with $100M+ incremental growth from LIVMARLI expansion and CTEXLI launch.
- Strategic priorities: global commercial growth, pipeline advancement (volixibat, MRM-3379), selective BD, and financial discipline.
- Recent milestones: PFIC U.S. & EU approvals, CTEXLI FDA approval, and EXPAND trial initiation.

**【CMO Pipeline Update】**
- **Volixibat (IBAT inhibitor):** 
  - PSC (VISTAS): 20-patient Phase III study on track for 2026 readout; interim data shows efficacy in pruritus reduction.
  - PBC (VANTAGE): 2026 enrollment completion; 2/3 of patients are first-line (pre-OCA).
  - Breakthrough Therapy Designation for PBC pruritus.
- **LIVMARLI (EXPAND):** Phase III trial for cholestatic pruritus (excluding PSC/PBC/ICP) on track for 2026 enrollment; 1,000+ U.S./EU patient prevalence estimated.
- **MRM-3379 (PDE4D inhibitor):** Fragile X Phase II study planned for 2025; PDE4D pathway active in neurodevelopmental disorders.

**【CFO Financial Summary】**
- Q4 2024 net product sales: $99.4M (+43% YoY), with LIVMARLI at $64.1M and bile acids at $35M.
- Full-year 2024 operating expenses: $424.5M (R&D: $140.6M, SG&A: $202.2M, COGS: $81.6M).
- Cash position: $293M at year-end (up $7M vs. 2023 start); 2025 guidance for positive cash flow.
- 2025 financial targets: $420-435M net product sales, continued cost control, and selective BD.

**【Q&A Highlights】**
- **Business Development:** CEO emphasizes financial flexibility for rare disease acquisitions, citing $293M cash balance and 2025+ pipeline visibility.
- **Fragile X (MRM-3379):** $1B+ U.S. market potential for 50,000 male patients; mechanism may expand to other neurodevelopmental disorders.
- **Alagille Penetration:** ~40% of eligible U.S. patients on LIVMARLI; growth driven by new diagnoses and weight-based dose escalation.
- **CTX Impact:** CTEXLI expected to convert diagnosed chenodiol users to branded product; focus on earlier diagnosis to prevent disease progression.
- **Pipeline Timing:** VISTAS PSC data in 2026, VANTAGE PBC readout in 2027, and EXPAND cholestatic pruritus results in 2027.

Actual				-0.86	-0.93	-0.86	-1.43	-1.68	-1.45	-1.55	1.91	-1.17	-0.84	-1.02	-0.99	-0.8	-1.94	-0.57	-0.63	-0.54	-0.52	-0.3	-0.49	-0.3	-0.12	0.05	-0.1
Forecast				-0.8172	-0.8726	-0.9753	-0.7318	-0.7057	-0.6483	-1.7343	0.3033	-1.34	-1.14	-1.0485	-1.0039	-0.8886	-0.7954	-0.6283	-0.2401	-0.4203	-0.4723	-0.4494	-0.2584	-0.3299	-0.3263	-0.1402	0.0555
Surprise	0.00%	0.00%	0.00%	-5.24%	-6.58%	+11.82%	-95.41%	-138.06%	-123.66%	+10.63%	+529.74%	+12.69%	+26.32%	+2.72%	+1.38%	+9.97%	-143.90%	+9.28%	-162.39%	-28.48%	-10.10%	+33.24%	-89.63%	+9.06%	+63.22%	+135.66%	-280.18%

MIRM

MIRM fundamentals

MIRM Q4 2025 Earnings

Earnings Call

You can ask Aime

MIRM

MIRM fundamentals

MIRM Q4 2025 Earnings

Earnings Call

MIRM Earnings Call Summary for Q4/20254:30 PM on Feb 25, 2026

MIRM Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

MIRM Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

MIRM Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

MIRM Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime